{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:24:48Z","timestamp":1771935888977,"version":"3.50.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1212\/01.con.0000464177.73440.44","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T12:05:26Z","timestamp":1428062726000},"page":"397-414","source":"Crossref","is-referenced-by-count":6,"title":["Benign Brain Tumors and Tumors Associated With Phakomatoses"],"prefix":"10.1212","volume":"21","author":[{"given":"Mariza","family":"Daras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Kaley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","unstructured":"Ostrom QT Gittleman H Farah P et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013; 15 (suppl 2): ii1\u2013ii56. doi:10.1093\/neuonc\/not151.","DOI":"10.1093\/neuonc\/not151"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Braganza MZ Kitahara CM Berrington de Gonzalez A et al. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol 2012; 14 (11): 1316\u20131324. doi:10.1093\/neuonc\/nos208.","DOI":"10.1093\/neuonc\/nos208"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Benson VS Pirie K Schuz J et al. Mobile phone use and risk of brain neoplasms and other cancers: prospective study. Int J Epidemiol 2013; 42 (3): 792\u2013802. doi:10.1093\/ije\/dyt072.","DOI":"10.1093\/ije\/dyt072"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","unstructured":"Coureau G Bouvier G Lebailly P et al. Mobile phone use and brain tumours in the CERENAT case-control study. Occup Environ Med 2014; 71 (7): 514\u2013522. doi:10.1136\/oemed-2013-101754.","DOI":"10.1136\/oemed-2013-101754"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","unstructured":"Frei P Poulsen AH Johansen C et al. Use of mobile phones and risk of brain tumours: update of Danish cohort study. BMJ 2011; 343: d6387. doi:10.1136\/bmj.d6387.","DOI":"10.1136\/bmj.d6387"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","unstructured":"Repacholi MH Lerchl A Roosli M et al. Systematic review of wireless phone use and brain cancer and other head tumors. Bioelectromagnetics 2012; 33 (3): 187\u2013206. doi:10.1002\/bem.20716.","DOI":"10.1002\/bem.20716"},{"key":"e_1_3_1_8_2","unstructured":"The International Agency for Research on Cancer; Louis DN Ohgaki H Wiestler OD Cavenee WK editors. WHO classification of tumours of the central nervous system. 4th ed. Lyon France: World Health Organization 2007."},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","unstructured":"Brastianos PK Horowitz PM Santagata S et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013; 45 (3): 285\u2013289. doi:10.1038\/ng.2526.","DOI":"10.1038\/ng.2526"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","unstructured":"Clark VE Erson-Omay EZ Serin A et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7 KLF4 AKT1 and SMO. Science 2013; 339 (6123): 1077\u20131080. doi:10.1126\/science.1233009.","DOI":"10.1126\/science.1233009"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","unstructured":"Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957; 20 (1): 22\u201339. doi:10.1136\/jnnp.20.1.22.","DOI":"10.1136\/jnnp.20.1.22"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","unstructured":"Rogers L Barani I Chamberlain M et al. Meningiomas: knowledge base treatment outcomes and uncertainties: a RANO review. J Neurosurg 2015; 122 (1): 4\u201323. doi:10.3171\/2014.7.JNS131644.","DOI":"10.3171\/2014.7.JNS131644"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","unstructured":"Chamoun R Krisht KM Couldwell WT. Incidental meningiomas. Neurosurg Focus 2011; 31 (6): E19. doi:10.3171\/2011.9.FOCUS11220.","DOI":"10.3171\/2011.9.FOCUS11220"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","unstructured":"Kaley T Barani I Chamberlain M et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol 2014; 16 (6): 829\u2013840. doi:10.1093\/neuonc\/not330.","DOI":"10.1093\/neuonc\/not330"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","unstructured":"Smouha EE Yoo M Mohr K Davis RP. Conservative management of acoustic neuroma: a meta-analysis and proposed treatment algorithm. Laryngoscope 2005; 115 (3): 450\u2013454. doi:10.1097\/00005537-200503000-00011.","DOI":"10.1097\/00005537-200503000-00011"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","unstructured":"Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999; 89 (1): 1\u20136. doi:10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3<3.0.CO;2-8.","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Cichowski K Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001; 104 (1): 593\u2013604. doi:10.1016\/S0092-8674(01)00245-8.","DOI":"10.1016\/S0092-8674(01)00245-8"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","unstructured":"Hutt-Cabezas M Karajannis MA Zagzag D et al. Activation of mTORC1\/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target. Neuro Oncol 2013; 15 (12): 1604\u20131614. doi:10.1093\/neuonc\/not132.","DOI":"10.1093\/neuonc\/not132"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"DeBella K Szudek J Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000; 105 (3 pt 1): 608\u2013614. doi:10.1542\/peds.105.3.608.","DOI":"10.1542\/peds.105.3.608"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Listernick R Charrow J Greenwald M Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994; 125 (1): 63\u201366. doi:10.1016\/S0022-3476(94)70122-9.","DOI":"10.1016\/S0022-3476(94)70122-9"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","unstructured":"Walker L Thompson D Easton D et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006; 95 (2): 233\u2013238. doi:10.1038\/sj.bjc.6603227.","DOI":"10.1038\/sj.bjc.6603227"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","unstructured":"Yohay K. Neurofibromatosis type 1 and associated malignancies. Curr Neurol Neurosci Rep 2009; 9 (3): 247\u2013253. doi:10.1007\/s11910-009-0036-3.","DOI":"10.1007\/s11910-009-0036-3"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","unstructured":"Hersh JHAmerican Academy of Pediatrics Committee on Genetics. Health supervision for children with neurofibromatosis. Pediatrics 2008; 121 (3): 633\u2013642. doi:10.1542\/peds.2007-3364.","DOI":"10.1542\/peds.2007-3364"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","unstructured":"Rasmussen SA Yang Q Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001; 68 (5): 1110\u20131118. doi:10.1086\/320121.","DOI":"10.1086\/320121"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","unstructured":"Evans DG Moran A King A et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005; 26 (1): 93\u201397. doi:10.1097\/00129492-200501000-00016.","DOI":"10.1097\/00129492-200501000-00016"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","unstructured":"Plotkin SR Merker VL Muzikansky A et al. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol 2014; 35 (1): e50\u2013e56. doi:10.1097\/MAO.0000000000000239.","DOI":"10.1097\/MAO.0000000000000239"},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","unstructured":"Smith MJ Higgs JE Bowers NL et al. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations but absence of female severity effect on age at onset. J Med Genet 2011; 48 (4): 261\u2013265. doi:10.1136\/jmg.2010.085241.","DOI":"10.1136\/jmg.2010.085241"},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","unstructured":"Plotkin SR Stemmer-Rachamimov AO Barker FG 2nd et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009; 361 (4): 358\u2013367. doi:10.1056\/NEJMoa0902579.","DOI":"10.1056\/NEJMoa0902579"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","unstructured":"Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009; 4: 16. doi:10.1186\/1750-1172-4-16.","DOI":"10.1186\/1750-1172-4-16"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","unstructured":"Westhout FD Mathews M Pare LS et al. Recognizing schwannomatosis and distinguishing it from neurofibromatosis type 1 or 2. J Spinal Disord Tech 2007; 20 (4): 329\u2013332. doi:10.1097\/BSD.0b013e318033ee0f.","DOI":"10.1097\/BSD.0b013e318033ee0f"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","unstructured":"Antinheimo J Sankila R Carpen O et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 2000; 54 (1): 71\u201376. doi:10.1212\/WNL.54.1.71.","DOI":"10.1212\/WNL.54.1.71"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","unstructured":"Hulsebos TJ Plomp AS Wolterman RA et al. Germline mutation of INI1\/SMARCB1 in familial schwannomatosis. Am J Hum Genet 2007; 80 (4): 805\u2013810. doi:10.1086\/513207.","DOI":"10.1086\/513207"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","unstructured":"Piotrowski A Xie J Liu YF et al. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet 2014; 46 (2): 182\u2013187. doi:10.1038\/ng.2855.","DOI":"10.1038\/ng.2855"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","unstructured":"Merker VL Esparza S Smith MJ et al. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist 2012; 17 (10): 1317\u20131322. doi:10.1634\/theoncologist.2012-0162.","DOI":"10.1634\/theoncologist.2012-0162"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","unstructured":"MacCollin M Chiocca EA Evans DG et al. Diagnostic criteria for schwannomatosis. Neurology 2005; 64 (11): 1838\u20131845. doi:10.1212\/01.WNL.0000163982.78900.AD.","DOI":"10.1212\/01.WNL.0000163982.78900.AD"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","unstructured":"Osborne JP Fryer A Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci 1991; 615: 125\u2013127. doi:10.1111\/j.1749-6632.1991.tb37754.x.","DOI":"10.1111\/j.1749-6632.1991.tb37754.x"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","unstructured":"Tee AR Fingar DC Manning BD et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 2002; 99 (21): 13571\u201313576. doi:10.1073\/pnas.202476899.","DOI":"10.1073\/pnas.202476899"},{"key":"e_1_3_1_40_2","doi-asserted-by":"crossref","unstructured":"Roach ES Sparagana SPDiagnosis of tuberous sclerosis complex. J Child Neurol 2004; 19 (9): 643\u2013649.","DOI":"10.1177\/08830738040190090301"},{"key":"e_1_3_1_41_2","doi-asserted-by":"crossref","unstructured":"Kothare SV Singh K Chalifoux JR et al. Severity of manifestations in tuberous sclerosis complex in relation to genotype. Epilepsia 2014; 55 (7): 1025\u20131029. doi:10.1111\/epi.12680.","DOI":"10.1111\/epi.12680"},{"key":"e_1_3_1_42_2","doi-asserted-by":"crossref","unstructured":"Goh S Butler W Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 2004; 63 (8): 1457\u20131461. doi:10.1212\/01.WNL.0000142039.14522.1A.","DOI":"10.1212\/01.WNL.0000142039.14522.1A"},{"key":"e_1_3_1_43_2","doi-asserted-by":"crossref","unstructured":"Krueger DA Care MM Holland K et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363 (19): 1801\u20131811. doi:10.1056\/NEJMoa1001671.","DOI":"10.1056\/NEJMoa1001671"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","unstructured":"Maher ER Yates JR Harries R et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77 (283): 1151\u20131163. doi:10.1093\/qjmed\/77.2.1151.","DOI":"10.1093\/qjmed\/77.2.1151"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","unstructured":"Kim WY Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22 (24): 4991\u20135004. doi:10.1200\/JCO.2004.05.061.","DOI":"10.1200\/JCO.2004.05.061"},{"key":"e_1_3_1_46_2","doi-asserted-by":"crossref","unstructured":"Wilding A Ingham SL Lalloo F et al. Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet 2012; 49 (4): 264\u2013269. doi:10.1136\/jmedgenet-2011-100562.","DOI":"10.1136\/jmedgenet-2011-100562"},{"key":"e_1_3_1_47_2","doi-asserted-by":"crossref","unstructured":"Hanakita S Koga T Shin M et al. The long-term outcomes of radiosurgery for intracranial hemangioblastomas. Neuro Oncol 2014; 16 (3): 429\u2013433. doi:10.1093\/neuonc\/not201.","DOI":"10.1093\/neuonc\/not201"},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","unstructured":"Comi AM. Update on Sturge-Weber syndrome: diagnosis treatment quantitative measures and controversies. Lymphat Res Biol 2007; 5 (4): 257\u2013264. doi:10.1089\/lrb.2007.1016.","DOI":"10.1089\/lrb.2007.1016"},{"key":"e_1_3_1_49_2","doi-asserted-by":"crossref","unstructured":"Shirley MD Tang H Gallione CJ et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 2013; 368 (21): 1971\u20131979. doi:10.1056\/NEJMoa1213507.","DOI":"10.1056\/NEJMoa1213507"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1212\/01.CON.0000464177.73440.44","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:59:50Z","timestamp":1752155990000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/01.CON.0000464177.73440.44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1212\/01.CON.0000464177.73440.44"],"URL":"https:\/\/doi.org\/10.1212\/01.con.0000464177.73440.44","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}